(Albany, New York) – October 19, 2026 – The market dynamics for Gastroparesis are expected to witness significant growth driven by the rising disease burden, increasing awareness and diagnosis, and the growing demand for effective treatments to improve gastric motility and manage persistent gastrointestinal symptoms. Additionally, the development of emerging therapies such as Naronapride (ATI-7505), CIN-102 (deudomperidone), PCS12852 (YH12852), NG101 (metopimazine), and others is expected to influence the market.
DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Gastroparesis Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Gastroparesis, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Gastroparesis Market
According to DelveInsight, the United States Gastroparesis market was valued at approximately USD 150 million in 2025 and is projected to reach approximately USD 970 million by 2036, growing at a CAGR of approximately 18% during 2026–2036.
Among the seven major markets (7MM), the United States accounted for approximately 724,000 diagnosed prevalent cases of Gastroparesis in 2025.
Approximately 70% of diagnosed Gastroparesis patients are female, while males account for approximately 30% of diagnosed cases across the 7MM.
In the United States, diabetes was the leading identified etiology of Gastroparesis in 2025, accounting for approximately 57% of cases, followed by postsurgical cases at 15% and drug-induced cases at 11%.
Leading companies developing therapies for Gastroparesis include EVOKE Pharma, Renexxion, CinDome Pharma, Neurogastrx, Processa Pharmaceuticals, Intact Therapeutics, and others.
Promising emerging therapies include Naronapride (ATI-7505), CIN-102 (deudomperidone), PCS12852 (YH12852), and NG101 (metopimazine).
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/gastroparesis-market
Key Factors Driving the Gastroparesis Market
Rising Disease Burden and Improved Diagnosis: Gastroparesis is associated with delayed gastric emptying and can occur due to diabetes, postsurgical complications, medications, or unknown causes. Increasing awareness, improvements in diagnostic approaches, and the rising burden of diabetes are contributing to the identification and management of affected patients.
Increasing Demand for Effective Pharmacological Treatments: Current management includes dietary modifications, antiemetics, and prokinetic agents to improve gastric motility and alleviate symptoms. However, limitations associated with existing therapies, including safety concerns and inadequate symptom control in some patients, are creating a need for better-tolerated and more effective treatment options.
Advancements in Emerging Therapies: The Gastroparesis pipeline is evolving, with investigational therapies targeting gastrointestinal motility and symptom control through different mechanisms. Novel candidates such as Naronapride, CIN-102, PCS12852, and NG101 may expand treatment options as clinical development progresses and additional evidence becomes available.
Gastroparesis Competitive Landscape
Several companies are developing therapies for Gastroparesis, including EVOKE Pharma, Renexxion, CinDome Pharma, Neurogastrx, Processa Pharmaceuticals, and Intact Therapeutics.
Key therapies in development include Naronapride (ATI-7505), a selective 5-HT4 receptor agonist intended to improve gastrointestinal motility; CIN-102 (deudomperidone), an investigational prokinetic candidate; PCS12852 (YH12852), a 5-HT4 receptor agonist being investigated for its effects on gastric motility; and NG101 (metopimazine), an investigational antiemetic candidate.
These therapies aim to address important unmet needs in Gastroparesis management, particularly the need for improved gastric emptying, better symptom control, and treatment options with more favorable safety profiles.
Discover more about therapies set to shape the Gastroparesis market @ Gastroparesis Treatment Landscape
Recent Developments in the Gastroparesis Market
In March 2024, Renexxion Ireland and Dr. Falk Pharma GmbH announced that the US Food and Drug Administration (FDA) had cleared the Investigational New Drug Application (INDA) for naronapride for the treatment of patients with Gastroparesis.
What is Gastroparesis?
Gastroparesis is a digestive disorder characterized by delayed gastric emptying in the absence of a mechanical obstruction. The condition can cause symptoms such as nausea, vomiting, abdominal pain, bloating, and early satiety. Diabetes, postsurgical complications, certain medications, and idiopathic factors are among the causes associated with Gastroparesis. Treatment generally focuses on symptom management, dietary modifications, and improving gastric motility. However, limitations associated with existing treatments highlight the need for more effective and better-tolerated therapeutic options.
Gastroparesis Epidemiology Segmentation
The Gastroparesis epidemiology section provides insights into the historical and current Gastroparesis patient pool and forecasted trends across the leading markets. The Gastroparesis market report evaluates epidemiological trends over the study period 2022–2036 across the seven major markets (7MM), segmented into:
Total Diagnosed Prevalent Cases of Gastroparesis
Etiology-specific Cases of Gastroparesis
Gender-specific Diagnosed Prevalent Cases of Gastroparesis
Age-specific Diagnosed Prevalent Cases of Gastroparesis
Severity-specific Cases of Gastroparesis Based on Delayed Gastric Emptying
Treated Cases of Gastroparesis
Scope of the Gastroparesis Market Report
Therapeutic Assessment: Current treatment practices and emerging Gastroparesis therapies.
Gastroparesis Market Dynamics: Historical and forecasted market size, therapy-wise market share, drug uptake, and market outlook.
Key Companies: EVOKE Pharma, Renexxion, CinDome Pharma, Neurogastrx, Processa Pharmaceuticals, Intact Therapeutics, and others.
Key Therapies: Metoclopramide (GIMOTI), Naronapride (ATI-7505), CIN-102 (deudomperidone), NG101 (metopimazine), PCS12852 (YH12852), and others.
Competitive Intelligence Analysis: Assessment of the clinical pipeline, mechanisms of action, emerging treatments, and competitive landscape.
Unmet Needs and Market Assessment: Evaluation of patient burden, treatment challenges, market drivers, market barriers, pricing, reimbursement, and future growth opportunities.
To know more about Gastroparesis companies working in the treatment market, visit @ Gastroparesis Clinical Trials and Therapeutic Assessment
Table of Contents
Gastroparesis Market Report Introduction
Executive Summary for Gastroparesis
Key Events and SWOT Analysis of Gastroparesis
Gastroparesis Patient Share (%) Overview at a Glance
Gastroparesis Market Overview at a Glance
Gastroparesis Background and Overview
Gastroparesis Epidemiology and Patient Population
Country-Specific Patient Population of Gastroparesis
Gastroparesis Current Treatment and Medical Practices
Gastroparesis Unmet Needs
Gastroparesis Emerging Therapies
Gastroparesis Market Outlook
Country-Wise Gastroparesis Market Analysis (2022–2036)
Gastroparesis Market Access and Reimbursement of Therapies
Gastroparesis Market Drivers
Gastroparesis Market Barriers
Gastroparesis Appendix
Gastroparesis Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
